Related to Elan Sells Drug Technologies Business to Alkermes for $960M in Cash and Shares

• RXi and EyeGate Join Forces for Noninvasive Ocular Delivery of RNAi Therapeutics
  
• NHLBI Ploughs $65M Follow-On Funding into Nanotech-Based Therapies and Diagnostics
  
• Phase III Trial Shows Near Equivalence of Baxter’s Subcutaneous IG Therapy to IV Product
  
• Alkermes’ Vivitrol Gets FDA Okay to Treat Opioid-Dependent Patients
  
• FDA Asks for More Clinical Data Before Approving Lilly's Type 2 Diabetes Drug
  
• NeuroVive Taps to-BBB to Enhance Development of Its Stroke Treatment
  
• GSK Pays U.S. Govt $750M for Selling Contaminated and Substandard Drugs
  
• Hikma Buys Baxter’s Injectable Generics Business and Facilities for $112M in Cash
  
• Tate & Lyle to Manufacture Farnesene for Amyris
  
• Quotient and Bend Partner to Provide Formulation Expertise for Clinical Trial Design
  
• Markets Waver as BTG Announces £177M Cash and Shares Acquisition of Biocompatibles
  
• MonoSol and Midatech Establish JV to Develop Transbuccal Nanoparticle Insulin Film
  
• Novo Nordisk and Merrion Sign €1.5M Deal for Oral Formulation Technology
  
• Elan Pays Transition $9M in Amended Deal for Phase II Alzheimer Candidate
  
• DuPont Acquires Danisco in $6.3B Deal
  
• Biotie to Acquire CNS Therapeutics Firm Synosia in €93.6M All-Shares Deal
  
• Adventrx Wraps Up $22.5M Registered Direct Offering
  
• Celsion to Obtain $5M in Financing and Fast-Track Milestone Payments from Japanese Partner
  
• Ligand to Pay $35.5M for CyDex Pharmaceuticals
  
• To-BBB Scores €4M to Advance Doxorubicin-Based Drug into the Clinic